arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Nuvalent, Inc.

NUVL
$123.97 0.00 (0.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
7 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Nuvalent, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.0B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -33.2%
FCF / Share $-3.79
Trailing P/E
Price / Book 7.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Jul 14, 2026.

7-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-425.38M
↓ -63.1%
FCF / Share Free cash flow per share
$-3.79
↓ -35.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
21
Cash Quality
46

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters